Esperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biopharmaceutical company's stock.

A number of other research analysts have also commented on ESPR. Needham & Company LLC restated a "buy" rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a "neutral" rating and a $4.00 price target on the stock. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $8.00 price objective for the company. Finally, JMP Securities reissued a "market outperform" rating and issued a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Esperion Therapeutics has an average rating of "Hold" and a consensus target price of $6.75.

Remove Ads

Esperion Therapeutics Stock Up 0.9 %

Esperion Therapeutics stock traded up $0.02 during mid-day trading on Thursday, hitting $1.71. The company had a trading volume of 2,983,192 shares, compared to its average volume of 5,940,485. Esperion Therapeutics has a 1 year low of $1.47 and a 1 year high of $3.94. The business has a fifty day moving average of $1.84 and a 200 day moving average of $2.07. The stock has a market cap of $337.33 million, a price-to-earnings ratio of -2.66 and a beta of 1.04.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio purchased a new stake in Esperion Therapeutics during the third quarter worth about $606,000. Anson Funds Management LP purchased a new position in Esperion Therapeutics in the 3rd quarter valued at approximately $540,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company's stock worth $1,174,000 after purchasing an additional 295,378 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Esperion Therapeutics by 66.8% in the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company's stock worth $995,000 after buying an additional 241,512 shares in the last quarter. Finally, Wasatch Advisors LP grew its position in shares of Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock valued at $38,521,000 after purchasing an additional 6,483,070 shares during the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.